INT190520

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.53
First Reported 2006
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 24
Total Number 26
Disease Relevance 20.08
Pain Relevance 5.60

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Hmgb1) extracellular region (Hmgb1) cell morphogenesis (Hmgb1)
nucleolus (Hmgb1) chromosome (Hmgb1) nucleus (Hmgb1)
Anatomy Link Frequency
hepatocytes 2
livers 1
brain 1
neutrophil 1
T cell 1
Hmgb1 (Mus musculus)
Pain Link Frequency Relevance Heat
antagonist 24 100.00 Very High Very High Very High
cytokine 519 99.96 Very High Very High Very High
Nicotine 95 99.76 Very High Very High Very High
agonist 81 99.44 Very High Very High Very High
Inflammation 512 99.36 Very High Very High Very High
ischemia 298 99.24 Very High Very High Very High
cva 73 98.04 Very High Very High Very High
chemokine 95 95.76 Very High Very High Very High
Bioavailability 7 95.04 Very High Very High Very High
Inflammatory response 258 89.32 High High
Disease Link Frequency Relevance Heat
Sepsis 945 99.78 Very High Very High Very High
Shock 20 99.60 Very High Very High Very High
Targeted Disruption 41 99.58 Very High Very High Very High
INFLAMMATION 898 99.36 Very High Very High Very High
Cv General 4 Under Development 11 99.24 Very High Very High Very High
Cancer 1481 98.72 Very High Very High Very High
Cv Unclassified Under Development 289 98.56 Very High Very High Very High
Endotoxemia 64 98.22 Very High Very High Very High
Hemorrhage 82 98.04 Very High Very High Very High
Adhesions 29 96.28 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Importantly for our experimental paradigm, however, blocking HMGB1 alone was sufficient to completely abrogate the efficacy of the antiglioma treatment.
Negative_regulation (blocking) of HMGB1
1) Confidence 0.53 Published 2009 Journal PLoS Medicine Section Body Doc Link PMC2621261 Disease Relevance 1.09 Pain Relevance 0.12
We used two different inhibitors of HMGB1 to block the activity of the putative endogenous TLR2 ligand during the combined immunotherapy-induced tumor regression.
Negative_regulation (inhibitors) of HMGB1 associated with cancer
2) Confidence 0.53 Published 2009 Journal PLoS Medicine Section Body Doc Link PMC2621261 Disease Relevance 0.77 Pain Relevance 0.04
Further, T cell-dependent tumor regression failed in vivo in TLR2 knockout mice, or mice where HMGB1 is either depleted or functionally inactivated.
Negative_regulation (depleted) of HMGB1 in T cell associated with targeted disruption and cancer
3) Confidence 0.53 Published 2009 Journal PLoS Medicine Section Body Doc Link PMC2621261 Disease Relevance 0.87 Pain Relevance 0.05
Inhibition of HMGB1 In Vivo with Glycyrrhizin and Depleting Anti-HMGB1 Antibodies
Negative_regulation (Inhibition) of HMGB1
4) Confidence 0.53 Published 2009 Journal PLoS Medicine Section Body Doc Link PMC2621261 Disease Relevance 0.06 Pain Relevance 0
Taken together, these data suggest that EGCG confers protection against lethal sepsis partly by inhibiting HMGB1 cytokine activities.


Negative_regulation (inhibiting) of HMGB1 associated with sepsis and cytokine
5) Confidence 0.42 Published 2007 Journal PLoS ONE Section Body Doc Link PMC2048740 Disease Relevance 0.29 Pain Relevance 0.18
Consistently, agents (e.g., catechin or ethyl gallate) incapable of inhibiting HMGB1-cell surface clustering uniformly failed to inhibit HMGB1-mediated cytokine production.
Negative_regulation (inhibiting) of HMGB1 associated with cytokine
6) Confidence 0.41 Published 2007 Journal PLoS ONE Section Body Doc Link PMC2048740 Disease Relevance 0.07 Pain Relevance 0.23
Although EGCG-mediated suppression of HMGB1 cell surface clustering may not account for its inhibitory effects on LPS-induced HMGB1 release, it likely underlies its inhibitory effects on cytokine activities of the secreted HMGB1.
Negative_regulation (suppression) of HMGB1 associated with cytokine
7) Confidence 0.41 Published 2007 Journal PLoS ONE Section Body Doc Link PMC2048740 Disease Relevance 0.26 Pain Relevance 0.20
In looking for anti-inflammatory therapeutic strategies, we have also found ethyl pyruvate and alpha7nAcChR agonist choline posses a potential inhibition of HMGB1 leading to improvement of animal survival after hemorrhage or sepsis [5–7].
Negative_regulation (inhibition) of HMGB1 associated with inflammation, agonist, cva and sepsis
8) Confidence 0.40 Published 2010 Journal Mediators of Inflammation Section Body Doc Link PMC2902015 Disease Relevance 2.48 Pain Relevance 0.52
Neutralizing antibody or “A-box”, a truncated DNA-binding domain, acts as a competitive inhibitor of HMGB1.
Negative_regulation (inhibitor) of HMGB1
9) Confidence 0.40 Published 2010 Journal Mediators of Inflammation Section Body Doc Link PMC2902015 Disease Relevance 1.16 Pain Relevance 0.12
Blocking HMGB1 activity in vivo using glycyrrhizin or specific anti-HMGB1 neutralizing antibodies, inhibited Flt3L/TK-induced brain tumor regression.
Negative_regulation (Blocking) of HMGB1 in brain associated with brain tumor
10) Confidence 0.39 Published 2009 Journal PLoS Medicine Section Body Doc Link PMC2621261 Disease Relevance 0.92 Pain Relevance 0.05
Glycyrrhizin binds to both box domains within HMGB1 [40,63] and thus prevents subsequent HMGB1 signaling; specific polyclonal blocking antibodies to HMGB1 [39,77–80] inactivate HMGB1 by binding to it, and reducing its bioavailability.
Negative_regulation (prevents) of HMGB1 associated with bioavailability
11) Confidence 0.39 Published 2009 Journal PLoS Medicine Section Body Doc Link PMC2621261 Disease Relevance 0.74 Pain Relevance 0.05
Inhibition of extracellular HMGB1 activity in vivo using either blocking antibodies or glycyrrhizin resulted in the complete failure of our therapy (Figure 7D).
Negative_regulation (Inhibition) of HMGB1
12) Confidence 0.39 Published 2009 Journal PLoS Medicine Section Body Doc Link PMC2621261 Disease Relevance 0.75 Pain Relevance 0.03
One of
       the most selective HMGB1 inhibitors, TSN IIA-SS, has already been used in China as a
       medicine for patients with cardiovascular disorders (Ref. 138). 
Negative_regulation (inhibitors) of HMGB1
13) Confidence 0.38 Published 2008 Journal Expert Reviews in Molecular Medicine Section Body Doc Link PMC2586610 Disease Relevance 0.23 Pain Relevance 0.07
With a limited number of effective therapies available for patients with sepsis, it is
       important to search for other agents capable of inhibiting clinically accessible late
       mediators, such as HMGB1. 
Negative_regulation (inhibiting) of HMGB1 associated with sepsis
14) Confidence 0.38 Published 2008 Journal Expert Reviews in Molecular Medicine Section Body Doc Link PMC2586610 Disease Relevance 0.76 Pain Relevance 0.04
Notably, the ‘A
           box’ of HMGB1 functions as an antagonist of HMGB1 (Refs 80, 81), whereas the
           ‘B box’ recapitulates the cytokine activity of full-length HMGB1
           (Refs 82, 83).
Negative_regulation (antagonist) of HMGB1 associated with antagonist and cytokine
15) Confidence 0.38 Published 2008 Journal Expert Reviews in Molecular Medicine Section Body Doc Link PMC2586610 Disease Relevance 0.45 Pain Relevance 0.38
Recently, a number of structurally diverse, multifunctional, ubiquitous host proteins
         – such as HMGB1 and heat shock protein 72 (HSP72) – have been
         categorised as ‘alarmins’ based on the following shared properties
         (Ref. 50) (Fig.
           2). 
Negative_regulation (number) of HMGB1 associated with shock
16) Confidence 0.38 Published 2008 Journal Expert Reviews in Molecular Medicine Section Body Doc Link PMC2586610 Disease Relevance 0.39 Pain Relevance 0.09
Will any specific HMGB1 inhibitor ever become a therapeutic agent for human sepsis?
Negative_regulation (inhibitor) of HMGB1 associated with sepsis
17) Confidence 0.38 Published 2008 Journal Expert Reviews in Molecular Medicine Section Body Doc Link PMC2586610 Disease Relevance 0.17 Pain Relevance 0.05
Loss of cytoplasmic HMGB1 paralleled the detection in the effluent; supporting the hypothesis HMGB1 was indeed released by damaged hepatocytes.
Negative_regulation (Loss) of HMGB1 in hepatocytes
18) Confidence 0.38 Published 2010 Journal Mediators of Inflammation Section Body Doc Link PMC3010695 Disease Relevance 0.62 Pain Relevance 0.20
For instance, a recent study indicated that reactive oxygen species
       (ROS) may oxidise HMGB1 to form an intramolecular disulphide bond between the thiol group of
       Cys106 and Cys23 or Cys45, and consequently abolish HMGB1-mediated immunostimulatory
       activities (Ref. 151). 
Negative_regulation (abolish) of HMGB1
19) Confidence 0.38 Published 2008 Journal Expert Reviews in Molecular Medicine Section Body Doc Link PMC2586610 Disease Relevance 0.13 Pain Relevance 0.05
A similar release pattern of HMGB1 was also observed in explanted BN livers, which were subjected to 24?
Negative_regulation (pattern) of HMGB1 in livers
20) Confidence 0.38 Published 2010 Journal Mediators of Inflammation Section Body Doc Link PMC3010695 Disease Relevance 1.30 Pain Relevance 0.42

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox